ReCell Cleared for Sales in China
Avita Medical Ltd has secured regulatory approval for its ReCell® Autologous Spray-On Skin from the Chinese State Food and Drug Administration (SFDA). ReCell has been issued an unrestricted import license. The SFDA is responsible for regulation and supervision of medical products and is the competent authority for drug regulation in mainland China.
Dr William Dolphin, CEO of Avita Medical, said, “China is a key market for the company’s products. ReCell addresses the growing demand for cosmetic surgery, scar revision and burns treatment. The product is being targeted to China’s burgeoning middle class, a rapidly growing segment of the country’s 1.3 billion people.”
The target market for ReCell includes plastic and reconstructive surgeons, dermatologists, burns specialists and cosmetic specialists at high end military hospitals as well as larger private hospitals in major metropolitan centres of China.
Other news from the department research and development
